Given that delivery of mRNA-based genome editing tools to CD34+ HSPCs has previously been shown to be efficient and well tolerated, an mRNA-based platform of prime editing in human CD34+ HSPCs could very well be an intriguing approach to both ex vivo and in vivo treatment of monogenic blood disorders. The gene discussed is CD34; the disease is hematologic disorder.